Twist Bioscience Corp
For the period ended Dec 31, 2025. Filed Feb 2, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
On November 22, 2025, Melissa Starovasnik, a member of the Company'sboard of directors, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”). Ms. Starovasnik’s 10b5-1 Plan provides for the potential sale of up to 4,500 shares of the Company’s common stock and will expire on the earlier of November 25, 2026 or the date when all shares under Ms. Starovasnik’s 10b5-1 Plan are sold.
On December 12, 2025, Robert Chess, a member of the Company'sboard of directors, adopted a 10b5-1 Plan. Mr. Chess' 10b5-1 Plan provides for the potential sale of up to 10,000 shares of the Company’s common stock and will expire on the earlier of December 11, 2026 or the date when all shares under Mr. Chess' 10b5-1 Plan are sold.
Other than as described above, during the three months ended December 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.